WO2007128674A3 - Muscarinic agonists to treat impulse control disorders - Google Patents

Muscarinic agonists to treat impulse control disorders Download PDF

Info

Publication number
WO2007128674A3
WO2007128674A3 PCT/EP2007/053934 EP2007053934W WO2007128674A3 WO 2007128674 A3 WO2007128674 A3 WO 2007128674A3 EP 2007053934 W EP2007053934 W EP 2007053934W WO 2007128674 A3 WO2007128674 A3 WO 2007128674A3
Authority
WO
WIPO (PCT)
Prior art keywords
impulse control
control disorders
disorder
biting
compounds
Prior art date
Application number
PCT/EP2007/053934
Other languages
French (fr)
Other versions
WO2007128674A2 (en
Inventor
Bruin Natasja M W J De
Drimmelen Marlies L Van
Arnoldus H J Herremans
Martinus Th M Tulp
Cornelis G Kruse
Original Assignee
Solvay Pharm Bv
Bruin Natasja M W J De
Drimmelen Marlies L Van
Arnoldus H J Herremans
Martinus Th M Tulp
Cornelis G Kruse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002649917A priority Critical patent/CA2649917A1/en
Application filed by Solvay Pharm Bv, Bruin Natasja M W J De, Drimmelen Marlies L Van, Arnoldus H J Herremans, Martinus Th M Tulp, Cornelis G Kruse filed Critical Solvay Pharm Bv
Priority to PL07728391T priority patent/PL2023909T3/en
Priority to MX2008014112A priority patent/MX2008014112A/en
Priority to AU2007247231A priority patent/AU2007247231B2/en
Priority to AT07728391T priority patent/ATE448778T1/en
Priority to BRPI0710699-8A priority patent/BRPI0710699A2/en
Priority to JP2009508308A priority patent/JP2010501471A/en
Priority to EA200870498A priority patent/EA014915B1/en
Priority to DE602007003348T priority patent/DE602007003348D1/en
Priority to EP07728391A priority patent/EP2023909B1/en
Publication of WO2007128674A2 publication Critical patent/WO2007128674A2/en
Publication of WO2007128674A3 publication Critical patent/WO2007128674A3/en
Priority to IL194778A priority patent/IL194778A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The invention relates to a novel use of compounds and pharmaceutically acceptable salts thereof, which are muscarinic, in particular muscarine-1 (M1) agonists. These compounds are useful for the preparation of medicaments for treatment, amelioration or prevention of impulse control disorders. These include impulse control disorders 'Not Elsewhere Classified' such as intermittent explosive disorder, pyromania, kleptomania, pathological gambling and trichotillomania; and impulse control disorders 'Not Otherwise Specified' such as: compulsive buying disorder, binge eating and binge drinking disorder, impulsive self-injurious behaviour such as pathological skin picking, nail-biting and nose-picking, gouging, head banging and self- biting; paraphilic sexual addictions, including exhibitionism, fetishism, frotteurism, pedophilia, masochism, sadism, transvestic fetishism and voyeurism; compulsive Internet use and excessive mobile phone use.
PCT/EP2007/053934 2006-05-04 2007-04-23 Muscarinic agonists to treat impulse control disorders WO2007128674A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BRPI0710699-8A BRPI0710699A2 (en) 2006-05-04 2007-04-23 use of a muscarinic agonist
PL07728391T PL2023909T3 (en) 2006-05-04 2007-04-23 Muscarinic agonists to treat impulse control disorders
MX2008014112A MX2008014112A (en) 2006-05-04 2007-04-23 Muscarinic agonists to treat impulse control disorders.
AU2007247231A AU2007247231B2 (en) 2006-05-04 2007-04-23 Muscarinic agonists to treat impulse control disorders
AT07728391T ATE448778T1 (en) 2006-05-04 2007-04-23 MUSCARIN AGONISTS FOR THE TREATMENT OF IMPULSE CONTROL DISORDERS
CA002649917A CA2649917A1 (en) 2006-05-04 2007-04-23 Muscarinic agonists to treat impulse control disorders
JP2009508308A JP2010501471A (en) 2006-05-04 2007-04-23 Muscarinic agonists for treating impulse dysregulation
EP07728391A EP2023909B1 (en) 2006-05-04 2007-04-23 Muscarinic agonists to treat impulse control disorders
DE602007003348T DE602007003348D1 (en) 2006-05-04 2007-04-23 MUSCARIN AGONISTS FOR THE TREATMENT OF IMPULSE CONTROL DISORDERS
EA200870498A EA014915B1 (en) 2006-05-04 2007-04-23 Muscarinic agonists to treat impulse control disorders
IL194778A IL194778A0 (en) 2006-05-04 2008-10-22 Muscarinic agonists to treat impulse control disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79735506P 2006-05-04 2006-05-04
EP06113476.3 2006-05-04
US60/797,355 2006-05-04
EP06113476 2006-05-04

Publications (2)

Publication Number Publication Date
WO2007128674A2 WO2007128674A2 (en) 2007-11-15
WO2007128674A3 true WO2007128674A3 (en) 2008-04-03

Family

ID=38544084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/053934 WO2007128674A2 (en) 2006-05-04 2007-04-23 Muscarinic agonists to treat impulse control disorders

Country Status (12)

Country Link
EP (1) EP2023909B1 (en)
JP (1) JP2010501471A (en)
KR (1) KR20090013815A (en)
AT (1) ATE448778T1 (en)
AU (1) AU2007247231B2 (en)
CA (1) CA2649917A1 (en)
DE (1) DE602007003348D1 (en)
EA (1) EA014915B1 (en)
ES (1) ES2336275T3 (en)
IL (1) IL194778A0 (en)
PL (1) PL2023909T3 (en)
WO (1) WO2007128674A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2296471A4 (en) 2008-05-15 2012-03-14 Univ Toledo Muscarinic agonists as cognitive enhancers
CA2804215C (en) 2009-07-22 2019-10-01 Eric Elenko Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
KR101613245B1 (en) 2015-04-27 2016-04-18 주식회사 대웅제약 Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
AU2019346626B2 (en) 2018-09-28 2022-06-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0525879A1 (en) * 1991-07-26 1993-02-03 Akzo Nobel N.V. Pyrazole derivatives
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders
WO2006017614A1 (en) * 2004-08-05 2006-02-16 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine to treat human neuropsychiatric disease
WO2006067494A1 (en) * 2004-12-23 2006-06-29 Minster Research Limited Sabcomeline alone or combined with a mood stabilising or antimanic agent to treat bipolar disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
TW200530246A (en) * 2003-12-19 2005-09-16 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0525879A1 (en) * 1991-07-26 1993-02-03 Akzo Nobel N.V. Pyrazole derivatives
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders
WO2006017614A1 (en) * 2004-08-05 2006-02-16 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine to treat human neuropsychiatric disease
WO2006067494A1 (en) * 2004-12-23 2006-06-29 Minster Research Limited Sabcomeline alone or combined with a mood stabilising or antimanic agent to treat bipolar disorders

Also Published As

Publication number Publication date
AU2007247231A1 (en) 2007-11-15
CA2649917A1 (en) 2007-11-15
EP2023909A2 (en) 2009-02-18
WO2007128674A2 (en) 2007-11-15
EA200870498A1 (en) 2009-04-28
EP2023909B1 (en) 2009-11-18
AU2007247231B2 (en) 2012-05-31
ES2336275T3 (en) 2010-04-09
EA014915B1 (en) 2011-02-28
IL194778A0 (en) 2009-08-03
JP2010501471A (en) 2010-01-21
PL2023909T3 (en) 2010-04-30
KR20090013815A (en) 2009-02-05
ATE448778T1 (en) 2009-12-15
DE602007003348D1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
IL194778A0 (en) Muscarinic agonists to treat impulse control disorders
HK1225642A1 (en) Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
WO2006099541A3 (en) Therapeutic wound care product
HUE050998T2 (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2007018797A8 (en) Selective nerve stimulation for the treatment of eating disorders
HK1084037A1 (en) Medicament for treating severe heart failure
WO2010042163A3 (en) Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
EP2397159A3 (en) Combination of morphinan compounds and antidepressant for the treatment of intractable and chronic pain
EP2192901A4 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2008030367A3 (en) Selective myostatin inhibitors
IL171930A (en) IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION , MEDICAMENTS CONTAINING THEM AND USE THEREOF FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT AND PREVENTION OF mGlu5 RECEPTOR MEDIATED DISORDERS
WO2008077557A8 (en) 8-ethinylxanthine derivatives as selective a2a receptor antagonists
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2006008316A3 (en) Selective inhibitors of human corticosteroid syntheses
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
NZ595545A (en) Compositions and methods for prophylaxis and treatment of addictions
EG24784A (en) Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments and pharmaceutical comprising them.
WO2007112121A3 (en) Tetracycline compounds and methods of treatment
WO2007039123A3 (en) Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
ZA200700823B (en) Treatment of CCR2 mediated diseases or disorders
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
WO2008048996A3 (en) Sequential combination therapy
WO2010127096A3 (en) Novel therapeutic treatments using centhaquin
WO2008094054A3 (en) 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders
WO2007115286A3 (en) Combinations of therapeutic agents for treating cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780016154.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07728391

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007728391

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2649917

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 194778

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007247231

Country of ref document: AU

Ref document number: 2009508308

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/014112

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 5983/CHENP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007247231

Country of ref document: AU

Date of ref document: 20070423

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200870498

Country of ref document: EA

Ref document number: 1020087029621

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0710699

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081022